EditorialA pharmacist packs a bottle of antiviral pills at the pharmacy at the Ogwedhi Health Centre in Migori, Kenya, Nov. 23, 2022. (Malin Fezehai/The New York Times)
EditorialDr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, on screen, testifies before the Senate Health Committee in Washington, June 16, 2022. (Haiyun Jiang/The New York Times)
EditorialPeople at a cafe in the West Village neighborhood of Manhattan on Monday, May 16, 2022, the day before virus cases hit the high alert level in New York City. (Amir Hamja/The New York Times)
EditorialA patient with pills of Paxlovid, the more powerful of the two COVID-19 antiviral pills approved by the Food and Drug Administration, at her home in Santa Barbara, Calif., Jan. 6, 2021. (Alex Welsh/The New York Times)
EditorialDonald Davis, one of the participants in the clinical trial of Pfizer’s antiviral pill, stands for a portrait in Sugarland, Texas on Oct. 1, 2021. (Michael Stravato/The New York Times)
EditorialPresident Donald Trump with, from left, Vice President Mike Pence, Daniel O'Day, CEO of Gilead, and Stephen Hahn, FDA commissioner, in the Oval Office at the White House in Washington, May 1, 2020. (Erin Schaff/The New York Times)
EditorialDr. Sean Conley, the White House physician, speaks during a briefing at Walter Reed National Military Medical Center in Bethesda, Md., where President Donald Trump is undergoing treatment for the coronavirus, on Saturday, Oct. 3, 2020. (Anna Moneymaker/The New York Times)
EditorialVice President Mike Pence, and Daniel O'Day, the CEO of Gilead, in the Oval Office of the White House while meeting with President Donald Trump in Washington, Friday, May 1, 2020. (Erin Schaff/The New York Times)